News
Sarepta Shares Fall
Digest more
The European Union’s health regulatory agency did not endorse approving Elevidys for ambulatory patients with Duchenne ...
Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock declined 13% Friday after European regulators recommended against approving Elevidys, the company’s gene therapy for Duchenne muscular dystrophy.
Sarepta downgraded as company suspends guidance after latest Elevidys death Jun. 16, 2025 11:31 AM ET Sarepta Therapeutics, Inc. (SRPT) Stock RHHBY, RHHBF By: Dulan Lokuwithana, SA News Editor 8 ...
Sarepta shares fell ~40% in premarket after reporting a second patient death linked to Elevidys. Sarepta halted Elevidys shipments for non-ambulatory patients and paused dosing in the ENVISION ...
Acute serious liver injury is already listed in the “Warnings and Precautions” section of Elevidys’ label, and Sarepta has been looking to update it after the first death. The two fatal ...
Nevertheless, on the same day, Sarepta assured investors that “the benefit-risk of ELEVIDYS remains positive.” Next, on June 15, 2025, Sarepta announced that a second patient treated with ...
Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne Provided by Business Wire Jun 14, 2025, 10:00:00 PM ...
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS, the only approved gene therapy for patients with Duchenne ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback